Chenopodium quinoa

Chenopodium quinoa has been studied in 3 papers since 2021: 1 trial in people, 1 in animals, 1 review; 1 in the past year. It has not reached trials in people. The newest paper, Feb 4, 2026: “Quinoa Improves Glucose Metabolism and Fluctuation Based on β-Cell Function in Early-Stage Type 2 Diabetes Mellitus: A Randomized Study”.

InterventionPreclinical

3 papers study it8 findingsUpdated

MeSH

More supplements

See all 3 papers on chenopodium quinoa

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“reductions in postprandial blood glucose (4.57 ± 2.7 mmol/L vs 2.2 ± 2.8 mmol/L, P <0.001)”
Quinoa Improves Glucose Metabolism and Fluctuation Based on β-Cell Function in Early-Stage Type 2 Diabetes Mellitus: A Randomized StudyInternational journal of general medicine2026doi:10.2147/ijgm.s584727

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Funder: Shandong University
  • Human trial1
  • Animals1

Studies in people

1 study gave chenopodium quinoa to people and measured what changed.

What changedDesignPeopleSource

down: Decreases postprandial blood glucose4.57 ± 2.7 mmol/L vs 2.2 ± 2.8 mmol/L

down: Decreases HbA1c0.86 ± 0.24 vs 0.28 ± 0.23

up: Increases time in range

Randomized trial14 weeks60 peoplebetween 20 and 70 yearsPatients with early-stage T2DMInternational journal of general medicine, Feb 4, 2026

What did studies of chenopodium quinoa find?

4

Studies of chenopodium quinoa measured 4 outcomes, among them medication reduction or withdrawal, time in range and HbA1c.

Medication reduction or withdrawal

upin humans1

1 study
  1. Chenopodium quinoa increases medication reduction or withdrawal in humans (28.6% vs 7.1%).

    Human trial14 weeksn = 60

  2. Chenopodium quinoa increases medication reduction or withdrawal in humans (early-stage T2DM) (28.6% vs 7.1%, P =0.036).

    Human trialearly-stage T2DMn = 60

Time in range

upin humans1

1 study
  1. Chenopodium quinoa increases time in range in humans.

    Human trial14 weeksn = 60

  2. Chenopodium quinoa increases time in range in humans (early-stage T2DM) (94.52 ± 4.88% vs 87.83 ± 9.9%, P <0.05).

    Human trialearly-stage T2DMn = 60

More on Time in range

HbA1c

downin humans1

1 study
  1. Chenopodium quinoa decreases HbA1c in humans (0.86 ± 0.24 vs 0.28 ± 0.23).

    Human trial14 weeksn = 60

  2. Chenopodium quinoa decreases HbA1c in humans (early-stage T2DM) (0.86 ± 0.24 vs 0.28 ± 0.23, P =0.042).

    Human trialearly-stage T2DMn = 60

More on HbA1c

Postprandial blood glucose

downin humans1

1 study
  1. Chenopodium quinoa decreases postprandial blood glucose in humans (4.57 ± 2.7 mmol/L vs 2.2 ± 2.8 mmol/L).

    Human trial14 weeksn = 60

  2. Chenopodium quinoa decreases postprandial blood glucose in humans (early-stage T2DM) (4.57 ± 2.7 mmol/L vs 2.2 ± 2.8 mmol/L, P <0.001).

    Human trialearly-stage T2DMn = 60

More on Postprandial blood glucose

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months